Podcasts about In vivo

New Zealand's wine industry could suffer as a result of Donald Trump's new tariffs, with the United States our largest export market. Invivo co-founder Rob Cameron spoke to Ingrid Hipkiss.

We love to hear from our listeners. Send us a message. After nearly five years as host of the Business of Biotech podcast, Matt Pillar is handing the mic over to the voice of the Business of Biotech 2.0, veteran life sciences journalist Ben Comer. On this epsiode, Ben shares his nearly 20-year journey covering the pharmaceutical space, from Haymarket Media to PwC to Pharmaceutical Executive and InVivo magazines, before joining Life Science Connect as Chief Editor at Life Science Leader. He shares stories of the wild ride he's enjoyed along the way, how the stories he's covered have shaped his editorial perspective, and his plans for the next chapter of the Business of Biotech podcast. Catch Ben's first episode as host next Monday, and every Monday after that. Subscribe to the podcast on your preferred platform and watch the videocast at lifescienceleader.com.Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at bioprocessonline.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceconnect.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

In Vivo spoke with UK biotech CEO Catherine Pickering about developing innovative therapies for challenging cancer types, the progress of iOntura's lead asset, roginolisib, for uveal melanoma, and the strategies that have helped secure over €100m in private financing.

New Zealand winemakers are continuing to make moves in the US. Amid an uncertain market, we were the only nation in the top ten US wine suppliers to increase its volume last year. Data suggests it's the 16th year in a row New Zealand wine has reported growth. Invivo Wine Founder Tim Lightbourne told Mike Hosking there's big opportunities over in the States, with New Zealand wines being sold right around the country. LISTEN ABOVE See omnystudio.com/listener for privacy information.

In Vivo spoke with Tran Le and Sohit Gatiganti, co-founders of Grove AI and developers of Grace, a voice-based agentic AI that streamlines clinical trial processes.

Harness Therapeutics' CEO talked to In Vivo about the company's scientific strategy, and its plans for expansion and partnering in the neurodegeneration space.

In Vivo speaks with Ashley Zender, CEO of Fauna Bio, a company using AI to identify drug targets based on natural disease resistance in animals. The company's $494m partnership with Eli Lilly is a testament to the value of their approach.

Juho Jalkanen, CEO of Faron Pharma, discusses the importance of addressing unmet medical needs in cancer through breaking treatment resistance and developing long-term solutions. In Vivo questions the current progress of their lead asset BEXMAB and its potential moving forward.

As we enter 2025, In Vivo convened a group of biotech executives for a wide-ranging conversation about dealmaking this year and the challenges and opportunities for companies in the cardiometabolic, longevity, radiopharmaceuticals and cancer spaces. Essential listening before JPM.

In this episode of the In Vivo podcast, Harvard immunologist and co-founder of early-stage biotech Corner Therapeutics, Jonathan Kagan, talks about harnessing the power of the innate immune system by weaponizing dendritic cells and creating immunotherapies that are safer and more durable.

How do you start a wine making partnership with Sarah Jessica Parker? It turns out, all you have to do is ask - as long as you have an award-winning wine brand and savvy business partners with years of experience. In this special episode, we have the pleasure of speaking with New Zealanders and business partners Tim Lightbourne and Rob Cameron of Invivo - where Rob is the winemaker and Tim is the director. After getting their degrees in physiology and one of them starting a pain relief cream business (not a joke), these childhood friends found themselves at a pub in England and hatched the plan for Invivo wines. Years of sweat and grit got them to where they are today, with an internationally known and distributed wine brand, and collaborations with Graham Norton and Sarah Jessica Parker. And in case you think these are just names slapped on the labels, Tim and Rob ensure that Norton and SJP are directly involved in the blending of their wines. Listen in to hear about their fascinating story, how storytelling is at the center of what they are trying to create, and learn more about their motto “Break Dumb Rules.”Send us a Text Message and we'll respond in our next episode!Contact The Wine Pair Podcast - we'd love to hear from you!Visit our website, leave a review, and reach out to us: https://thewinepairpodcast.com/Follow and DM us on Instagram: https://www.instagram.com/thewinepairpodcast/Send us an email: joe@thewinepairpodcast.com

In this episode of the In Vivo podcast, Peter Flynn, CEO of Arialys Therapeutics, discusses the exciting field of autoimmune neuropsychiatry and the company's monoclonal antibody, which it is investigating for the treatment of a rare condition called anti-NMDA receptor encephalitis and potentially other indications.

In this episode of the In Vivo podcast, Michelle Werner, CEO of Alltrna, discusses using tRNA as a therapeutic modality for rare diseases, including those stemming from nonsense mutations.

Does wine feel too complicated? In this episode of Wine Talks, Paul K sits down with Tim Lightbourne and Rob Cameron, the founders of Invivo Wines, to explore how they've transformed the wine industry. Ditching the stuffy, aristocratic vibe traditionally associated with wine, Invivo has redefined the game with bold creativity and a focus on fun and inclusivity. They reveal the power of their celebrity collaborations with Sarah Jessica Parker and Graham Norton–partnerships that go beyond simple endorsements. Discover how Invivo is pushing the boundaries of wine marketing, including launching their winery airline and hosting quirky blending sessions designed to craft the perfect wine bottle. This episode is truly a masterclass in balancing authenticity with wine branding, navigating industry challenges, and rewriting the rules in a competitive market. Don't miss this eye-opening conversation!   Key Takeaways: Introduction (00:00) Invivo's “100% bullshit-free” wine philosophy (00:38)  Making wine accessible for younger consumers (02:16) How Rob and Tim pioneered equity crowdfunding in wine (06:00) Invivo's founding story and innovative marketing (09:08) Understanding consumer tastes and regional differences (12:06) Invivo's innovative celebrity collaborations (22:09) Wine industry's need for creativity and marketing innovation (44:17) Episode wrap-up (48:13)   Additional Resources:

In the latest episode of the In Vivo podcast, Noam Solomon, co-founder and CEO of Israeli-American biotech Immunai explains how his company is mapping the immune system and using AI to predict individual immune responses to drugs. Noam also discusses the company's own acquisitions, partnerships, the differences between innovation and invention, artificial biomedical intelligence (ABI) and barriers to personalized medicine.

EP653 셀럽술 2-2 [인비보(Invivo) X] (시음) '사라 제시카 파커‘가 협업한, 뉴질랜드 소비뇽블랑의 맛은?

Americans seem to love New Zealand wine. Grafton-based Invivo was flying off US shelves, selling more than 40,000 cases of sauvignon blanc in 2024 alone. It's set to be on show in Times Square at an exclusive wine exhibition this week, run by Wine Spectator. Co-founder Tim Lightbourne told Mike Hosking that both New Zealand wine and sauvignon blanc are growing as categories in the US market. He said that wine as a whole is relatively flat and driven by cabernets and chardonnays, so there's room to NZ sauvs to grow. LISTEN ABOVE See omnystudio.com/listener for privacy information.

EP652 셀럽술 2-1 [인비보(Invivo) X] 섹스앤더시티 '사라 제시카 파커‘가 협업한 소비뇽블랑 와인

Richard Lowenthal, co-founder, and CEO of ARS Pharma, highlights the crucial unmet need for needle-free injections. Challenging issues posed by current epinephrine injectors, In Vivo questions the current and future progression of Neffy.

In the latest episode of the In Vivo podcast, Russ Lebovitz, the co-founder and scientist behind Amprion, a diagnostics company, discusses the role of alpha-synuclein misfolding in neurodegenerative diseases and how early alpha-synuclein detection has the potential to mitigate the impacts of diseases ranging from Parkinson's disease to Lewy body dementia.

In the latest episode of the In Vivo podcast, Alan Aspuru-Guzik, a pioneer in chemical engineering who holds many positions, talks about how he is folding in robotic automation, generative AI and quantum computing in his self-driving lab.

Tom Salemi, editorial director of DeviceTalks shares his accidental yet fulfilling journey into the medtech industry. Tom reveals his passion for storytelling, building communities, and highlighting the human aspect of medical device innovation. He discusses the evolution of DeviceTalks, its focus on collaboration and education, and the importance of personal connections within the industry.    Guest links: devicetalks.com Charity supported: Feeding America Interested in being a guest on the show or have feedback to share? Email us at podcast@velentium.com.  PRODUCTION CREDITS Host: Lindsey Dinneen Editing: Marketing Wise Producer: Velentium   EPISODE TRANSCRIPT Episode 036 - Tom Salemi Lindsey Dinneen: Hi, I'm Lindsey and I'm talking with MedTech industry leaders on how they change lives for a better world. Diane Bouis: The inventions and technologies are fascinating and so are the people who work with them. Frank Jaskulke: There was a period of time where I realized, fundamentally, my job was to go hang out with really smart people that are saving lives and then do work that would help them save more lives. Diane Bouis: I got into the business to save lives and it is incredibly motivating to work with people who are in that same business, saving or improving lives. Duane Mancini: What better industry than where I get to wake up every day and just save people's lives. Lindsey Dinneen: These are extraordinary people doing extraordinary work, and this is The Leading Difference. Hello, and welcome back to The Leading Difference podcast. I'm your host Lindsey and I am so excited to be speaking with my guests today. Tom Salemi. Tom is the editorial director of DeviceTalks. He tells medtech stories with wonder, humor, and great respect. He hosts podcasts, conducts video interviews and organizes events, both virtual and in-person to ensure our innovative medtech ecosystem stays strong and saves lives. All right. Well, thank you so much for being here, Tom. I'm so excited to talk with you this morning. Tom Salemi: Oh, it's my pleasure. Thanks for having me. It's great to be on this other side of the podcast interview experience. Lindsey Dinneen: Yeah, absolutely. Well, I would love if you wouldn't mind starting off by sharing just a little bit about yourself and your background and how you wandered into medtech. Tom Salemi: Sure. I'm a Massachusetts native, lived here my whole life. Always was aware of the healthcare industry, but I can't say I had a long time love for it or anything like that. My parents were not doctors. I am not an engineer, nor ever could be, but I did go to journalism school. And I wasn't quite sure why, it just always appealed to me. I went to visit a newspaper once, the Boston Herald, and I fell in love with the newsroom. It just seemed like the most fun place to be in the world. So I wanted to work there for a living, but later on, I think I found out it was more, I really enjoy building communities and that's gonna, I think, develop later on. I found my way into medtech quite accidentally. I was at a local paper in Massachusetts and wanted to get a job at the Boston Business Journal 'cause I was tired of covering city council meetings and planning board meetings about the height of fences and things like that. And the only beat that was open was healthcare. And at the time, this was '97, that included all the Boston hospitals, the biotechs, and the medical device companies. So it was a lot, but it was intriguing. And, I'll say my parents at the time were older and starting to see doctors more and more. So I was like, "Well, it wouldn't be the worst thing in the world to understand that industry a bit better." So I took the job at the Business Journal and then that led to an invitation to edit a venture capital newsletter that focused again, broadly on healthcare. So, that was in '98, it's called Venture Capital and Healthcare. Very very descriptive name. And from there, I just really grew to love medtech. I mean, biotech, is of course bigger and fascinating in its own right, but I never quite understood the whole molecule thing, whereas devices, you could see what this thing did and what it looked like. And how the pump worked and why I moved the blood this way or that way. It was just I think an easier and a better story for me to tell. So that's how I wandered my way into healthcare and into medical devices. Lindsey Dinneen: Wonderful. Thank you for sharing. Well, and now with DeviceTalks, can you tell us a little bit about DeviceTalks, and maybe a little bit about what you're excited about for it for the future? Because I know there's just so much in the works and it just keeps growing and it's so exciting to watch. Tom Salemi: Yeah, no, it's been an interesting development. So I joined actually DeviceTalks in 2019. It existed prior to me. It's been around for 10 years or so. It was a sort of the events business related to the Mass Device news site. So, prior to that, I was writing for magazines, wrote for InVivo and Startup. And then decided in 2014, I was I was done with writing. I just wanted to do something different. And at the same time, the company that acquired our magazine decided they wanna lay off the editorial staff. So it was it was quite a good bit of timing for me 'cause I don't think I ever would've got off the branch without a little boot in the butt. So I started doing conferences for a smaller company, medical device conferences, and podcasts. And then the opportunity to join DeviceTalks again happened in 2019 to, to run their three meetings. Of course, 2020 came around. I joined November, 2019, four months later the world shut down and we didn't have our events. So, we pivoted and launched our podcasts and our webinars and went back to events in 2022. DeviceTalks' mission has been really focused on the people who make medical devices, who design them, who manufacture them, who get them through the regulatory process. Anyone who touches a medical device from inception to handling it to a physician to have it implanted in a patient. We try to track that whole process. We do a bit of sort of the venture capital stuff, which was where my interests were lying previously. But DeviceTalks' goal is really again, to focus on the engineers and manufacturing folks, those who were really on the front lines of making medical devices. DeviceTalks has sort of morphed over time from just an events business to our podcast business, which is not only our weekly podcast, but we're working with a lot of the major OEMs to help them tell their stories through podcasts. We're continuing to roll out new series focused on specific OEMs or specific areas. We'll have a neuro one coming out soon. We'll have a structural heart one coming out soon. And we still, the DeviceTalks Tuesdays program that we launched in May 2020, because we couldn't meet the person, we did virtual like everybody else. I thought it would be something that would go away when we went back to in person, but it's only grown. So we'll continue. We continue to do about 35 of those a year. We take a month off in August and then a few days here and there for holidays. But next year we're going to be expanding that to bring some more kind of issues and OEM oriented conversations. So people seem to have responded to the opportunities to talk about medtech all the time and to listen to medtech all the time. So, as the host of a podcast, it's a pretty great time to be producing stories like these. Lindsey Dinneen: Yeah, absolutely. Well, thanks for sharing a little bit about DeviceTalks and its trajectory. It's so exciting to see how it continues to grow and evolve over time. And yeah, it's been interesting to watch how so many companies have changed, obviously because of the pandemic, but then sometimes it's been a really interesting change where, what you thought was going to happen doesn't actually happen the way, but it's exciting. And, you just keep moving with it. So that's great. Tom Salemi: I was listening to the first podcast we did in March 2020,. Chris Newmark and I were talking about, "Well, what does this mean? Like, are we not going to go to meetings? Are we going to have these conversations online? Like digitally? That's crazy. That doesn't make any sense." And we just literally described the world today, but we were both just flabbergasted, "This is nuts. This is just not going to work." So you're right. Things are evolved quickly. Lindsey Dinneen: Yeah. Yeah. And it's great. So, you're coming at the medtech industry from a really unique perspective, and you are telling stories and sharing stories about people's, incredible devices and innovations and the journey from concept to actually producing something. And I'm curious how does that storytelling process work for you? Like how do you go about finding the hidden gems within a founder's story, and then being able to take that and really run with it so that it's not just a matter of, "Hey, this device is incredible. Look at all the shiny, cool, amazing things it does. But here's the purpose and the reason behind that, too." Tom Salemi: That's a good question. I mean, I, like you, start the podcast with the stories about the guests, 'cause I'm really intrigued by their path into medtech. 'Cause I don't think it's, we know the industry itself isn't extraordinarily sexy. It's not on the front page of the Wall Street Journal. We're not talking about, well, these stupid app names that are missing vowels and people seem to get excited about it. We're a very kind of, I don't know, low key industry, but we're the industry, the people who make these devices, are literally saving lives. So I think the guests that we talk to, you know, come to it come to this industry for a purpose. You obviously can build a very successful career for yourself. But I really do enjoy trying to find out what that why is and how it came to be, how it came to lead to a career in medtech. And then I really focused down on, we've all had those moments where we've made life decisions and we could have gone this way or that way. And we chose that way. And it worked out, but what was that? What was the thought process at that fork in the road? And why was that decision made? 'Cause I think really, I think that's something that everyone can connect with. I remember talking with Mike Mahoney, the CEO of Boston Scientific at DeviceTalks Boston last year, talking about his indecision as to whether he was going to take the job at Boston Scientific. He was obviously a senior medtech guy at J& J. Why leave J& J for Boston Scientific, which was struggling at the time? And he just told this great story of how he had hired a consultant to review the situation and to give him a recommendation. The consultant was like, "No way, man, stay at J& J, you're doing great." And he was going to interview at Boston with the intention, I think, of saying no. And then he just took a moment and walked off and just looked in a mirror and said, "Do you want to do this or not?" And he said, "Yeah, I want to do this." And he just went for it and look what happened. So, I think finding those human moments in medtech is important because, more so than tech, in other industries, I think it is a very human industry because, again, people are here for a personal reason. Many people have personal stories as to why they entered medtech. Talk to people who have lost childhood friends, when they were teenagers and that drove them to medtech, obviously the state of our parents, in my case, draws you here. I think very often there's a compassionate thread. I mean, sometimes people just, maybe they go into sales 'cause they see the cars in the parking lot of, and I think there's that and that's fine too, but I think those people also come around to, "Oh wait, this is, I can have my cake and eat it too. I can actually do some good while doing well." So, I do like to focus on the human part of our industry. And I think it's one that needs to be told more because too often it's a conversation focused on FDA approvals or recalls, and we're just talking about the machinery and not the people who make it. Lindsey Dinneen: Yes. Very well said. And I completely agree with you. I think there's, oftentimes a little bit of, because to your point, it's not sort of on the front pages every day. And I will venture to say that sometimes when it is, it's for the reasons we don't want it to be. So, so it's so important to tell these stories. And the thing is, I came in from also from an outside perspective and my background is marketing and business development, business strategy. And so when I came in, it was a whole new world as well. And one thing that I realized is from an outside perspective, sometimes there's this sort of unfair stigma about people are in it solely for the money. And honestly, It's a really hard industry to be in if that's your only goal. So I think, telling these stories about these founders and the why behind it is just so compelling. And I love being able to do that. I'm so glad that you do that all the time as well. Yeah. Tom Salemi: Yeah, no it's just, those are things that need to be reported on and focused on more, so I'm glad we're both shining a light on it. Lindsey Dinneen: Yeah, absolutely. So, okay. So I know that DeviceTalks, it has so many different facets to it. One of the really interesting things that you guys do is put on events. And I was wondering if you could speak a little bit to that process and even just there, there are a number of different industry events available, but DeviceTalks pretty special. So I was wondering if you could talk to a little bit about that element and what makes it unique. Yeah. Tom Salemi: Yeah. No. So when I joined in 2019, I came aboard to help find a direction, a different direction for the meetings to focus it more on the engineering and the device making, which was going to be challenging for me. 'Cause my, again, I really focused more on who raised series A, and who raised series B, and who's a late stage investor, and who's an early stage investor. And for me, for a long time prior, medical device coverage was just, you report on the company's financings, your report on their FDA approval. And then, I don't know, all that stuff in between and who knows what happens there. So, COVID in a way presented an opportunity because we were able to focus on the podcasts and really give me an opportunity to learn about the industry, to learn about the engineering and the manufacturing about it, but also to get to know the device companies themselves and the comms teams there. So, by the time we resumed things in 2022, it sort of afforded me the opportunity to really work with the comms teams at the big companies, and the engineers and the folks who had on podcast, and try to get those stories that we told on the podcast on stage and maybe a grander fashion. Maybe there's a PowerPoint vote. Maybe there's two or three people who can talk about pulse field ablation, who can talk about the orthopedic business, who can talk about surgical robotics. So DeviceTalks, although we include some of that in our conversations, partnership and financing, especially in Boston, we've got The Medtech Innovator there and they run a great innovation, sort of forum investment forum. I just love working with Paul Grand and I love The Medtech Innovator crowd. And I still love startups, the folks who start companies are just absolutely insane in a good way. God bless them. I love it. And so, but I really wanted to give an opportunity for the Strykers, for the Boston Scientifics, for the Medtronics to come and sit down in sort of a collegial atmosphere and say, "Look, this is, this is the device we're working on. These were the challenges we had in developing it. This is how we're looking at the patient population." And just go over different challenges that that they had overcome. So it really, I think, is an opportunity for everyone to sit down and talk about the designing, the making, even the selling. We're actually getting more into the selling of medical devices to talk about the business of medical devices in a very, almost. I don't want-- collegiate sounds weird-- but just a very educational, sort of open setting. So we'll do, we have our keynotes, we'll have our big CEO keynotes. We'll have a venture panel from time to time. And like I said, we'd love to have the startups present, especially in Boston with MedTech innovator. We do that a little less of that at DeviceTalks West, but our bread and butter can sit continues to be engineering and manufacturing. And we really want folks to come down and talk about the intricacies behind their very cool and important and lifesaving devices, so people walk away with a better understanding of how to make their life saving device. And hopefully if they've taken the time to get to know this person who's achieved something great, and maybe they connect on LinkedIn, and it leads to a company being started five or six or 10 years down the road or two or three years down the road. Who knows? So we're all about again, open conversations about medical device development and about fostering the opportunity for personal connection as well. Lindsey Dinneen: I love that. Well, and I love your focus on collaboration, and education and that, the knowledge is shareable and it's really important and I think it's really impressive that you've created an atmosphere where people do want to come and share and talk about the good, the bad, and the ugly of their process and being able to share those stories, like you said, could very well inspire the next generation of innovators because it's important to be honest and transparent when you can be. So I think that's really incredible that you've fostered this atmosphere that, that leads to that. So. Tom Salemi: No, thank you. No, and I'm really grateful to those companies that take advantage. Sometimes folks will come and maybe their presentation is a little scripted. But I think just having that person in the room, the Chief Technology Officer or the Director of Engineering for some valve program is important. And it just gives people, I think as much as-- if I were to create a pie chart for the importance of stuff that goes with a bar graph that happens on stage versus like the 10 minutes after someone's on stage, it's probably the bars are probably pretty close. I'm not sure which is more important, but I think just getting everybody together and we've actually, I initially fought this, I'll admit it, but first couple of conferences, we had like five minutes in between sessions 'cause I just wanted to pack so much in. This year, our conference team was like, "Can we do 15 minutes?" And I was like, "No!" If you add it up, you've probably lost like 30 minutes of programming, but the 15 minutes was really great for just to give people some comfortable time to like, "Hey, I heard what you said about X. Here's something I'm working on, what do you think about that?" I think that those kinds of conversations are are very important and you can lead it up. You can leave it up to serendipity that, "Oh, if I'm at the conference and the Chief Technology Officer from major medtech is going to be there, I'll bump into him in the cocktail reception," but it's not always easy to do. So we try to, we really try to foster those connections so people get the insights they need and go home with some really positive insights and feedback. Lindsey Dinneen: I love that. Yeah, I absolutely love what your company does for that. That's incredible. Tom Salemi: Thank you. Lindsey Dinneen: So along your journey, have there been any moments where it stood out to you that you had this realization that "Yes, I am in the right industry at the right time." And just something, like a story that you got to share or something that just made you go, "Oh yes, I'm in the right place here." Tom Salemi: Interesting question. I mean, I have a lot of those moments. Some of those singular moments, I think, some are a just collective moment. Like I've said before, when I was covering the Newburyport City Council, there was literally a moment where they were arguing about the distance-- I was there supposed to be covering this meeting-- and they were talking about the height of fences. And I literally got up and just left. And I was like, "I can't spend, I don't want to dedicate another minute of my life to this." And I've never done anything like that before. I am this Joe Earnest, like I'm gonna stay to the end and make sure it goes. I had the whole journalism thing going on. But I was just like, "I just can't spend my life doing this." I've never, ever had that moment in medtech. I've never come to work and said, "Why am I writing about this? Or why am I talking to this person? Or what, what is this even about? What's the point?" I've never even thought that. And I would have that conversation if I were covering insurance or even, when I was at my newsletter, got a company by Dow Jones. And I thought my only path up was really to like get into news wires and start covering earnings and things like that. And I was like, " I don't want to be covering earnings and being measured by like, did I beat AP or whomever or Bloomberg by 35 seconds?" No, that's not what I want to do. I want to write about cool tech and talk to cool people. So that's when I left Dow Jones and joined EnVivo and Startup, cause I really wanted to focus on medtech. But, there are a lot of those moments where I'm really glad to be doing what I'm doing and there's singular moments too, where, I'm sitting in a plane and I look across the aisle and the woman next to me is just reading an EnVivo Magazine and she's got my article open. And I'm like, ah, I just want to tap her in the shoulder. " What do you think? What do you think about Right Medical, huh? Pretty interesting stuff, huh?" That was very cool. I remember interviewing Kevin Lobo at the early medtech conference I did in Minnesota. It just went super well. He's a really great guy to talk to and very easy to talk to, very open and honest, and will answer any question. But just getting off the stage was like, "Wow, that was a lot of fun. I want to go up and do another one." Which is weird, 'cause I wasn't a big stage guy before, but I don't know, the opportunity to dig and find some cool stories and really see the humanity in these medical device folks is a great challenge and a great privilege for me. I'm really blessed to have the access that I have. So I'm very grateful. Lindsey Dinneen: Amazing. Oh my gosh, I loved that so much. And yeah, I totally, it would be hard not to go, "Hey, what do you think?" Tom Salemi: Exactly, right? Yeah. Then what? Then like, "Oh yeah." Then she's like, "Sure. Sure. You're Tom Salemi." And then it gets really weird. "Oh really?" I let it be, but it's one of those forks in the road moments. What would have happened if I just asked her if she liked the right medical story and maybe who knows? I don't know. Lindsey Dinneen: That's so great. Tom Salemi: I might've had, I might've met a future CEO and then had a great story to tell with her someday. So. Lindsey Dinneen: It's still a possibility. Tom Salemi: it still happen. Lindsey Dinneen: Maybe you'll run into again. Tom Salemi: She's hearing this, maybe. She's like, "Wait a minute, I did read an EnVivo Magazine on the plane once next to some weird guy who was..." Lindsey Dinneen: "...weirdly watching me while I was reading it." Tom Salemi: Exactly, while was reading a magazine. Lindsey Dinneen: That's so funny. I love it. Well, pivoting the conversation just for fun. Imagine that you were to be offered a million dollars to teach a masterclass on anything you want. It can be within your industry, but it doesn't have to be. What would you choose to teach and why? Tom Salemi: Wow. People say "that's a great question" to me all the time. And I always like, "I don't really have that many great questions. Like one or two of them are great!" But that's a good, that's a really great question. Oh, wow. I think For me, learning to speak publicly and enjoy the time on stage, I think has been a real blessing for me. So, and I know a lot of people have that ability as well. I think that would be great thing to, to share with folks. But I think moreover, I mean, it's crazy to me that like people look to me like some sort of storytelling expert where I really just like, it's like, "You're really interesting. I'm not conjuring magic. You have a great story that you just don't know exists. I'm not some wizard who's just waving my wand and saying something in broken Latin and it all happens. It's all in you." And I wish folks could look inside and see their own stories and see the stories of others as well. And they're probably too busy designing that next great device that they don't really have that ability to look inward. But, I think helping people identify their own stories, not necessarily to tell them in a podcast form, but just to have a better sense of, of who they are. I mean, I've talked to a few people who like you, I'll say, "Oh, I'll start the conversation learning about you." And they'll say, "Well, I'm boring. Just talk about the company." And I said, "You're not boring. I've never talked to a boring person." Believe me, like everyone has great stories and everyone has great decisions that they made and, it's just a matter of telling it, or at least knowing those stories are in there. So, because I can't teach on anything of technical value, I guess I'll focus on that. Just helping people identify their own stories and and sharing them in the world in a way that's appropriate for them. Again, they don't have to have a YouTube channel, but they could just say, "Hey, I do important work. I'm interesting. And, I've made a difference in the world." That's pretty awesome. Lindsey Dinneen: Yes. Well, I love that. And I actually think the wizardry component of it comes in with allowing people to feel safe enough to tell their stories, and comfortable, because it can be harder, especially when you're maybe telling a story that is challenging for you, that talks about something where maybe things didn't go the way that you hoped they would, or you failed at something. And so, so giving people, providing that safe space, basically, to allow people to share those stories and encourage it is, I think you've got that wizardry component. Tom Salemi: Oh, I appreciate that. And that's a great point. And I think, like with the keynotes, when you're talking with someone who's willing to trust you a bit and say, "Look, when I do keynotes," I'm like, "Look, these are the things I want to talk about." Just allow me to, if I hear something interesting, I go, "Wait a minute, can I just pull that thread a moment," and just to have someone trust you that you're not going to take it in a really weird way, that you're going to see the positive, I think, is when you really have done your job and have a great keynote. Those are the moments, especially like at a conference where people walk away and say, "That was great." Keynotes should be really great and interesting. They can be informative as well, but if you're just focusing on, why you designed this over that and why that, why it's important to help people with this dreadful disease, all of that's important, but I think the stories that really resonate with people are the ones when they, where the people in the audience can really form a connection with the person on stage. I think that's when you really hit the home run. So, just trying to do that. Lindsey Dinneen: Yes. Yes. Yeah, absolutely. And I think to your point, another component that you do really well and that I think is important in that sort of wizardry aspect, is the respecting and honoring of the person's choosing to tell that story. So it is, like you said, drawing out the positive and honoring the fact that they've decided to share with you. And so therefore they continue to feel safe, and respected in sharing their insights and stories and whatnot. So I think you're absolutely right that it has to have multi layer components. And, and I love your thing. You've never met a boring person. That's so great. That's so true. Tom Salemi: It's true. I mean, just talk to people. My son is going to be an engineer and he's like already 10 times smarter than I am technically. I teach him how to jump a car battery and he's explained to me, "Oh yeah, that's why the red has to be attached to the black." And I'm like, "I don't know that. I just know red and black. Don't tell me why the battery works. I don't really need to know that. I just need to know how not to set my car on fire." That's where my technical knowledge. But there are people in the world who understand how things work. And I just-- that's witchcraft. To understand, why planes fly and why batteries work. That stuff's amazing to me. Lindsey Dinneen: I agree. I agree. All right. And so, on a bit of a more serious note, how would you like to be remembered after you leave this world? Tom Salemi: Oh, wow. I mean, like I said at the start, I got into journalism cause I thought it would be fun. And I was also a shy kid and I didn't want to be in a cubicle all my life, 'cause I think, I don't think I'd ever climb out of it. I wanted to really force myself into the world. But then I came to realize that what I really liked was helping people connect and I think that's becoming harder and harder for people to do, not to get too heavy about it, but I think there are a lot of lonely people in the world who aren't finding connection or the connections they are finding aren't necessarily the most productive. So I hope, I hope I, I ease that somewhat and I'm always --just last week, actually, I got a couple of great messages and I don't get a ton of these. It's just weird timing, but someone who said that they enjoy the podcast, and they're college students, and they went into biomed because of the podcast. They joined a startup competition. It's like, "Wow. I, with my stupid stories, I had an impact on someone in a positive fashion!" And I told this person, " Great. When you invent the lifesaving technology," I said, "I will take total credit because I'm the one who stirred you into medical devices." I'm getting a few of those nice messaging, and it's, I hope that people remember that, we have a lot more in common... I hope people will think that I've reminded people that we have a lot more in common than we do differences, and that we have a lot more positivity to rally around the negativity. And it's the only way we're going to get things done in this world is if we're working together on it. So if I could help that happen a little bit, I think I'd be happy with that as a life lived. Lindsey Dinneen: Yeah. Yeah, absolutely. Wow. And thanks for sharing that story. That's incredible. That is so exciting. Tom Salemi: I'm so grateful. I told him, I'm so grateful that person wrote, "thank you so much," 'cause that, yeah, that people don't do that very frequently. So it's awesome. Lindsey Dinneen: Yeah, and final question. What is one thing that makes you smile every time you see or think about it? Tom Salemi: Huh. My first thought was my, my kids just seeing them find their way through life, seeing them find the things that energize them. It's great when you see that. Dogs, of course would be a good one. Lindsey Dinneen: Yes. Tom Salemi: I love a good dog. I don't know, everything that's coming to mind, it sounds kind of corny. I mean, obviously when you see people take a kindness on somebody else, or be kind to someone else when they don't need to be, I think is extraordinarily uplifting. So my kids, my dogs, my dog, any dog, actually most dogs will do... Lindsey Dinneen: Yes. Tom Salemi: Yeah. But my dog in particular, but no, I think I just, those moments that, unfortunately, we're not shining enough light on where people are overly kind and helpful to each other. I think we need to see more of that at this time. Lindsey Dinneen: Yeah. Agreed. Well, I think that's phenomenal. I, I also am a huge dog lover. So anytime, I mean, really, it's like an instant happiness. Tom Salemi: Yeah. Lindsey Dinneen: Instant. So happy. So. Yeah, they are the best. Well, I just want to say this has been an incredible conversation. It's been so great to get to know you a little bit and also get to know a little bit more about the incredible work that DeviceTalks is doing. So I just want to thank you so much for being here and being willing to share your stories. This has been great. Tom Salemi: Oh, thank you so much. It was an honor to be asked. It doesn't happen frequently and it was-- you've got some great questions. I may steal a couple of them. So. Lindsey Dinneen: Absolutely. Well, thank you again. We are so honored to be making a donation on your behalf as a thank you for your time today to Feeding America, which works to end hunger in the United States by partnering with food banks, food pantries, and local food programs to bring food to people facing hunger. And they also advocate for policies that create long term solutions to hunger. So thank you for choosing that organization to support and thank you for all the work you do to change lives for a better world. Tom Salemi: Okay. Thank you so much. Lindsey Dinneen: Thank you also to our listeners. And if you're feeling as inspired as I am right now, I'd love it if you would share this episode with a colleague or two, and we will catch you next time. Ben Trombold: The Leading Difference is brought to you by Velentium. Velentium is a full-service CDMO with 100% in-house capability to design, develop, and manufacture medical devices from class two wearables to class three active implantable medical devices. Velentium specializes in active implantables, leads, programmers, and accessories across a wide range of indications, such as neuromodulation, deep brain stimulation, cardiac management, and diabetes management. Velentium's core competencies include electrical, firmware, and mechanical design, mobile apps, embedded cybersecurity, human factors and usability, automated test systems, systems engineering, and contract manufacturing. Velentium works with clients worldwide, from startups seeking funding to established Fortune 100 companies. Visit velentium.com to explore your next step in medical device development.

Welcome to the latest series of Fertility Foundations, where we speak in depth with expert guests about how to prepare the foundations for healthy pregnancy. This week Sandra Greenbank is talking to Sarah Nash, a registered Nutritional Therapist who specialises in PCOS, about IVF as a first-line treatment to try and conceive with PCOS. Sarah is passionate about supporting and educating women with PCOS and their partners on their journey to parenthood. In this episode Sandra and Sarah discuss the difficulties of diagnosing and treating PCOS and the need for a holistic approach to addressing the root cause and key drivers in each individual case. Sarah's own PCOS diagnosis in her twenties led her to specialising in this area and, now a mum to two children, she uses her knowledge and experience to support her nutritional therapy practice. You can find Sarah's website here: www.sarahnash.co.uk Or find her on Instagram here: @sarahnash_fertility   This podcast is sponsored by Invivo Healthcare, a human microbiome company. They specialise in accurate testing of different microbes such as the gut, vagina, oral and urinary, as well as a range of specially curated supplements focused on the microbiomes. They support healthcare providers and their clients navigate the complex world of the human microbiome and it's one of the most used labs and supplements by our own fertility specialists at the Fertility Nutrition Centre. Visit the Invivo website for more information at www.invivohealthcare.com. 

Welcome to the latest series of Fertility Foundations, where we speak in depth with expert guests about how to prepare the foundations for healthy pregnancy. This week Sandra Greenbank is talking to Debbie Cotton, Head of Clinical Innovation at Invivo Healthcare, about the vaginal microbiome and how this can affect fertility. In this episode Sandra and Debbie discuss the significance of the vaginal microbiome in fertility, looking at its impact on reproductive health. They highlight the importance of understanding and working with one's vaginal microbiome for optimal fertility outcomes, and provide insights into the role of nutritional therapy, microbiome testing and the potential harmful effects of conventional period products on not just the vaginal microbiome but also overall health. You can find more information about microbiome testing at Invivo's website here: www.invivohealthcare.com Or find them on Instagram here: www.instagram.com/invivohealthcare This podcast is sponsored by Invivo Healthcare, a human microbiome company. They specialise in accurate testing of different microbes such as the gut, vagina, oral and urinary, as well as a range of specially curated supplements focused on the microbiomes. They support healthcare providers and their clients navigate the complex world of the human microbiome and it's one of the most used labs and supplements by our own fertility specialists at the Fertility Nutrition Centre. Visit the Invivo website for more information at www.invivohealthcare.com. 

In this episode of the In Vivo podcast, Billy Boyle, CEO of Owlstone Medical, discusses how his company is developing several breath biopsy products for use by clinicians, biopharma companies and researchers.

Welcome to the latest series of Fertility Foundations, where we speak in depth with expert guests about how to prepare the foundations for healthy pregnancy. This week Sandra Greenbank is talking to Raquel Monroy about how to protect your mental health and stay positive when you're trying to conceive. Raquel is a registered Nutritional Therapist specialising in infertility and women's health. She helps those who are trying to conceive to optimise their diet and lifestyle to help them get pregnant and have the healthy baby they didn't think was possible. Throughout this episode Sandra and Raquel discuss the emotional challenges of infertility and the importance of seeking support, prioritising health, and practicing self-care. This podcast is sponsored by Invivo Healthcare, a human microbiome company. They specialise in accurate testing of different microbes such as the gut, vagina, oral and urinary, as well as a range of specially curated supplements focused on the microbiomes. They support healthcare providers and their clients navigate the complex world of the human microbiome and it's one of the most used labs and supplements by our own fertility specialists at the Fertility Nutrition Centre. Visit the Invivo website for more information at www.invivohealthcare.com. 

Fertility Foundations: Working with a Nutritional Therapist - my fertility journey with Stephanie Foxley   Welcome to the latest series of Fertility Foundations, where we speak in depth with expert guests about how to prepare the foundations for healthy pregnancy. This week Sandra Greenbank is talking to Stephanie Foxley about her fertility journey and what she learned from working with Jennifer Walpole, Nutritional Therapist. On discovering fertility issues, Stephanie and her husband were to undergo IVF treatment and sought help from the Fertility Nutrition Centre's Practitioner Jennifer Walpole prior to starting. Here, she shares her personal experience of addressing the underlying root causes of their infertility issues, taking control of nutrition and lifestyle, and considering the impact of diet and lifestyle on fertility. Throughout the episode Stephanie and Sandra discuss the benefits of holistic approaches and the importance of maintaining a healthy lifestyle during conception, pregnancy and postpartum. This podcast is sponsored by Invivo Healthcare, a human microbiome company. They specialise in accurate testing of different microbes such as the gut, vagina, oral and urinary, as well as a range of specially curated supplements focused on the microbiomes. They support healthcare providers and their clients navigate the complex world of the human microbiome and it's one of the most used labs and supplements by our own fertility specialists at the Fertility Nutrition Centre. Visit the Invivo website for more information at www.invivohealthcare.com. 

Fertility Foundations: My fertility journey - What I knew then and what I'd do differently now with Samantha Ferguson Welcome to the latest series of Fertility Foundations, where we speak in depth with expert guests about how to prepare the foundations for healthy pregnancy. This week Sandra Greenbank is talking to Samantha Ferguson about her personal experience and challenges. Throughout the episode Sandra and Samantha discuss their personal experiences and professional insights on addressing reproductive challenges through a holistic approach. They emphasise the importance of seeking professional help, supporting each other, and finding alternative approaches to fertility treatment. They also discuss the connection between nutrition and fertility, the importance of prioritising one's own health and eating well to support a loved one's recovery, as well as the need for self-care and conscious choices about diet and lifestyle to prevent long-term health problems. Find Samantha Ferguson on Instagram here: www.instagram.com/whatseatingher And find Sam's website here: www.sam-ferguson.co.uk This podcast is sponsored by Invivo Healthcare, a human microbiome company. They specialise in accurate testing of different microbes such as the gut, vagina, oral and urinary, as well as a range of specially curated supplements focused on the microbiomes. They support healthcare providers and their clients navigate the complex world of the human microbiome and it's one of the most used labs and supplements by our own fertility specialists at the Fertility Nutrition Centre. Visit the Invivo website for more information at www.invivohealthcare.com.

Mr. Happy | The Next Generation - Part 2Tune into the second half of our fascinating conversation with Joshua, A.K.A. Mr. Happy from the famous Mr. Happy Stack. We discuss more insight on how the microbiome, immune system, hormones and neurotransmitters are connected. These systems rely on us to exercise, to eat well, and to be able to recover. However, our lifestyle, food supply, and other factors can make it difficult to maintain a healthy baseline. And further, how do supplements play a part in all of this?Part 2 of the podcast is an activating deep-dive that motivates us to take our health seriously, and better understand the main factors that allow us to live long, healthy and happy lives. These are the immune system, the microbiome, the hormone biosynthesis system, and our diets.Click to Learn More About Joshua's Immune System Researchhttps://bornfree.life/understanding-the-model/6/updated-disease-model-wip/45/1:20 In Vivo vs. In Vitro5:20 The Importance of the Micro-Biome14:55 Mineral Deficiencies18:00 Dietary Minerals23:30 Bio-films and the Immune System28:00 Dopamine Synthesis and Nootropics35:00 Hormone Biosynthesis42:00 Testing Our Microbiome + Bacterias44:40 Getting to the Root of Hormonal Imbalance47:00 Are Male Testosterone Levels Dropping?50:00 NADH Supplementation56:00 The Importance of Exercise57:00 The Importance of Libido1:03:00 Which Tests Work Best for Microbiome1:05:30 Understanding Our Microbiome1:11:00 Conclusion

A Kiwi wine company has a unique approach to blending their new vintage.  Invivo is currently in New York where they, along with their partner Sarah Jessica Parker, will be blending their new vintage in the middle of Citi Field.  The field is the home stadium for the New York Mets, who have given them exclusive use of the empty stadium.  Co-founder Tim Lightbourne told Mike Hosking that they wanted to open their brand up to a wider audience instead of being enclosed in a room somewhere at a winery.  He said that in a market like America, you have to do things really different, and you can't just sit at home with your fingers crossed.  LISTEN ABOVE See omnystudio.com/listener for privacy information.

Today on the Daily Bespoke, the fellas are joined by Tim Lightbourne from Invivo...See omnystudio.com/listener for privacy information.

In this episode of the In Vivo podcast, Hakim Yadi, CEO and co-founder of UK techbio company Closed Loop Medicine, discusses how his company is pairing software and predictive analytics with medications old and new to tailor drug dosing to each patient.

This week Sandra Greenbank is talking to Natasha Evans, Nutritional Therapist and Health Coach, about a fully holistic, 360 degree approach to fertility and what that actually entails. Natasha firmly believes that the reason people are finding it increasingly difficult to conceive is because of the modern, unnatural world we're currently living in. A core part of Natasha's approach is to help people get back to nature, tune in to their body's innate wisdom and reconnect with what their bodies were designed to do.  As a result of her work, Natasha has founded the 'Fertility 360 Method: 9 Steps to 9 Months', a holistic, 360 degree approach to fertility and examining diet, lifestyle, environment, and supplementation. Sandra and Natasha examine the pillars of this approach throughout the podcast. Listen to this episode of the Fertility Foundations podcast with Natasha Evans here. Find Natasha Evans on Instagram here: www.instagram.com/nenutrition And find Natasha's website and a copy of her free guide 'The Fertility 360 Method: 9 Steps to 9 Months' here: www.nenutrition.co.uk This podcast is sponsored by Invivo Healthcare, a human microbiome company. They specialise in accurate testing of different microbes such as the gut, vagina, oral and urinary, as well as a range of specially curated supplements focused on the microbiomes. They support healthcare providers and their clients navigate the complex world of the human microbiome and it's one of the most used labs and supplements by our own fertility specialists at the Fertility Nutrition Centre. Visit the Invivo website for more information at www.invivohealthcare.com. 

Welcome to the latest series of Fertility Foundations, where we speak in depth with expert guests about how to prepare the foundations for healthy pregnancy. This week Sandra Greenbank is talking to Katy Bradbury, Registered Nurse and Nutritional Therapist, about what you can do if you're feeling lost and overwhelmed while trying to conceive.    As well as being a registered nurse and a nutritional therapist, Katy is qualified to work with people who have eating disorders and is trained in hypnosis and coaching the unconscious mind. Her approach to health uses a functional medicine model to delve deep into the underlying drivers behind personal imbalances and addressing them in a bespoke way.    Throughout this podcast Sandra and Katy discuss the connection between nutrition and fertility, the need for more education and awareness around this topic, and why a personalised approach to fertility nutrition is important.    Find Katy Bradbury on Instagram here: www.instagram.com/katybradburyhealth And find Katy's website here: https://www.katybradbury.com   This podcast is sponsored by Invivo Healthcare, a human microbiome company. They specialise in accurate testing of different microbes such as the gut, vagina, oral and urinary, as well as a range of specially curated supplements focused on the microbiomes. They support healthcare providers and their clients navigate the complex world of the human microbiome and it's one of the most use labs and supplements by our own fertility specialists at the Fertility Nutrition Centre. Visit the Invivo website for more information at www.invivohealthcare.com.     

Welcome to the latest series of Fertility Foundations, where we speak in depth with expert guests about how to prepare the foundations for healthy pregnancy. This week Sandra Greenbank is talking to Julia Young from Julia Young Nutrition.  Julia is passionate about supporting couples and women with their fertility and hormonal issues. Having gone through her own fertility struggles, Julia was diagnosed with polycystic ovarian syndrome (PCOS) and suffered from absent periods for seven years. Unable to conceive naturally, Julia and her husband underwent several rounds of fertility treatment and a miscarriage, and were finally blessed with two boys, one via IUI and one by IVF. After discovering the power of nutrition, lifestyle and supplements on the impact of her health, Julia trained as a registered Nutritional Therapist and now supports others struggling to conceive. Throughout this podcast Sandra and Julia discuss the importance of addressing the underlying root causes of Polycystic Ovarian Syndrome (PCOS) through nutrition, lifestyle, and functional approaches to promote healthy fertility and hormonal balance.  Find Julia Young on Instagram here: www.instagram.com/juliayoungnutrition And find Julia's website here: https://www.juliayoungnutrition.com Julia offers all listeners access to her proven 3-step method to optimising your fertility (without the overwhelm and confusion) with her free training, Nourish For Fertility. You can access it here: https://www.juliayoungnutrition.com/free-training This podcast is sponsored by Invivo Healthcare, a human microbiome company. They specialise in accurate testing of different microbes such as the gut, vagina, oral and urinary, as well as a range of specially curated supplements focused on the microbiomes. They support healthcare providers and their clients navigate the complex world of the human microbiome and it's one of the most use labs and supplements by our own fertility specialists at the Fertility Nutrition Centre. Visit the Invivo website for more information at www.invivohealthcare.com. 

With its potential to expand the horizons of what's possible for patients, CRISPR is the new darling of biotech. Reaching an important milestone in 2023 with the FDA approval of a sickle cell treatment using CRISPR, the technology is poised to break new barriers for treating patients in the near future. In this episode we talk with two companies working together on the next generation of CRISPR: editing cells within the body.  We discuss the progress and the challenge in making this breakthrough a reality. Follow us on LinkedIn, X, Facebook and Instagram. Visit us at https://www.bio.org/

Welcome to the latest series of Fertility Foundations, where we speak in depth with expert guests about how to prepare the foundations for healthy pregnancy. This week Sandra Greenbank is talking to Dr. Rahi Victory from Victory Reproductive Care. Dr. Victory is a board-certified Obstetrician, Gynecologist and infertility specialist dedicated to helping improve the reproductive health of men and women. He is a Fellow of the Royal College of Surgeons of Canada and Fellow of the American Congress of Obstetricians and Gynecologists. His passion for promoting reproductive health is reflected by his deep commitment to educating and helping patients, his active involvement in fertility research, and also for creating a multidisciplinary clinic environment that embraces patient-centred and holistic health care. Find Dr. Victory on Instagram here: www.instagram.com/rahivictory.md Follow him on YouTube here: www.youtube.com/@DrVictory or contact him on via the Victory Reproductive Care website: https://www.drvictory.com This podcast is sponsored by Invivo Healthcare, a human microbiome company. They specialise in accurate testing of different microbes such as the gut, vagina, oral and urinary, as well as a range of specially curated supplements focused on the microbiomes. They support healthcare providers and their clients navigate the complex world of the human microbiome and it's one of the most use labs and supplements by our own fertility specialists at the Fertility Nutrition Centre. Visit the Invivo website for more information at www.invivohealthcare.com.

In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.

In this episode, In Vivo speaks to 2024 Rising Leader Hanadie Yousef, CEO of Juvena Therapeutics, about her journey, the secretome as a source of therapeutics, longevity medicine and alternatives to GLP-1 inhibitors for obesity.

Vibhor Gupta, director and founder of Pangaea Data, talks to In Vivo about the value of identifying the 80% of patients with undiagnosed or misdiagnosed conditions, and how his company is addressing this need.

Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company's pipeline and recent data publication in the field of obesity. The company is focused on developing drugs that inhibit the NLRP3 inflammasome, a validated drug target that plays a pivotal role in controlling inflammatory diseases. It has two clinical trials ongoing – both Phase Ib/IIa – in Parkinson's disease and for cardiovascular risk in obese patients.

This episode is from a webinar presented by Dr. Clay Zimmerman, Director of Technical Services at Balchem. To view the full webinar and access the slides referenced during this podcast, visit balchem.com/realscience and scroll down to the webinar presented on December 12th, 2023.Dr. Zimmerman begins with an overview of Balchem's microencapsulation technologies in both human nutrition and health and animal nutrition and health businesses. (0:31)Encapsulation is a generic term, and huge differences can exist between products that protect the same compound. Balchem's microencapsulation technology consists of packaging a substance in a lipid capsule for protection. Encapsulates can differ in design, technology, and performance. When it comes to performance in ruminant encapsulates, stability in feed mixing and TMRs and animal performance are evaluated. (6:50)Lipid encapsulation usually comes in one of two forms, a matrix encapsulation or a true encapsulation. A good analogy for matrix encapsulation is chocolate chip cookie dough, where some active compound is always at the surface. In the rumen, this leads to reduced protection and stability. True encapsulation, often called single-layer or multiple-layer encapsulation, is analogous to an m&m where there is no active compound at the surface, and this leads to greater protection and stability in the rumen.  (12:00)So why do we encapsulate nutrients for ruminants? In general, for targeted delivery within the gastrointestinal tract of the animal because rumen fermentation often results in massive breakdown of most of these important compounds. For example, choline chloride is almost completely degraded in the rumen. (18:30)When developing or improving rumen-protected products for nutrients such as choline chloride, methionine, lysine, or niacin, the primary goal is to protect them as much as possible from ruminal degradation while achieving post-ruminal absorption. Once prototypes have good ruminal stability and good intestinal release, the next step is feed and mixing stability. Dr. Zimmerman goes on to showcase different research techniques for evaluating encapsulates in these three areas as well as in animal performance. (20:39)In summary, there are many differences in encapsulated products for dairy cows, due to the design of products; types, amount, and composition of coatings; manufacturing differences; and differences in nutrient content, bioavailability, and feed stability. True encapsulates, or multi-layered coating products, are preferred for ruminant applications due to their higher levels of ruminant and feed stability. Four really important features of a good ruminant encapsulate are good ruminal stability, good nutrient bioavailability, feed and TMR stability, and ultimately biological performance. (47:05)Dr. Zimmerman then answers questions from the webinar audiences about in vitro techniques and bioavailability, coating ingredients, the importance of base diet for rumen fluid donors in in vitro techniques, variation in products from in vitro to in vivo results, how long it takes to develop a new encapsulated product (Balchem spends years and even decades researching before a product release), and why nutrient contents differ so much in similar encapsulated products on the market. (49:58) Please subscribe and share with your industry friends to bring more people to join us around the Real Science Exchange virtual pub table.  If you want one of our new Real Science Exchange t-shirts, screenshot your rating, review, or subscription, and email a picture to anh.marketing@balchem.com. Include your size and mailing address, and we'll get a shirt in the mail to you.

In the latest episode of the In Vivo podcast, Edwin Stone, CEO of UK-based Cellular Origins, talks about how robotics can increase access to safe cellular therapies. The type of biology-agnostic robotics his company develops can help companies scale up cell manufacturing while lowering the cost of production.

In the latest episode of the In Vivo podcast, non-executive chair Peter Bains and Owain Millington, vice president of immunology and head of preclinical, discuss ILC Therapeutics' platform technology, financing plans as well as the pros and cons of running a startup biotech in the UK.

In this episode, In Vivo speaks to Bruce Leuchter, CEO of Neurvati Neurosciences, about ways clinical drug development in rare neurologic diseases is being held back and what can be done to make the process more efficient and successful.

In this podcast, In Vivo speaks to Sara Barrington, CEO of Verici DX. During the discussion, Barrington outlines the current challenges facing patients post-transplant, why current diagnostics are inadequate, and where the overall transplant market is headed, considering the rise of home dialysis and the potential future for xenotransplants.

Industry veteran and serial entrepreneur Daphne Koller tells In Vivo about how her company, Insitro, is unleashing the potential of computational biology and machine learning to discover new drug compounds.

In this latest instalment of the In Vivo podcast Daniel Lofaso, CEO of Digital Elevator, talks about the common mistakes biotech companies make when trying to build their brand, how to connect with varied audiences and key trends the industry should keep track of in digital marketing.

9xchange CEO Anat Naschitz and Benevolent AI's Matthew Fujisawa spoke with In Vivo about how they are trying to make selling and buying pharma assets more efficient through a digital marketplace and AI.

In 2016 Jason Kander was a rising star in the Democratic Party. After narrowly losing the race to become one of Missouri's Senators, he began laying the groundwork for a Presidential run. Jason unexpectedly pivoted to declaring his candidacy for the 2019 Kansas City mayoral election, and quickly became the clear favorite. Three months into that campaign he ended his candidacy and stepped back from public life after revealing that he had suffered from PTSD and depression after serving as an intelligence officer in Afghanistan in 2006 and 2007On today's episode of Being Well, Jason joins Forrest to talk about his personal journey recovering from PTSD, the impact of his time serving in Afghanistan, imposter syndrome and shame, having a mental health challenge in public, and what we can do to better support veterans. About our Guest: Jason is a former Missouri Secretary of State and member of the Missouri state legislature. He's current the President of National Expansion at Veterans Community Project, a non-profit organization dedicated to fighting veteran suicide and homelessness. He's also the host of Majority 54, a popular political podcast, and the author of Invisible Storm: A Soldier's Memoir of Politics and PTSD. If you're in crisis, are thinking about suicide, or are concerned about a loved one, please call 1-800-273-8255. The Lifeline network is available 24/7 across the United States.Watch the Episode: Prefer watching video? You can watch this episode on YouTube.Key Topics:0:00: Introduction1:45: Jason's experience coming to accept having PTSD3:45: Symptoms5:50: How the military (mostly doesn't) address PTSD8:00: Chronic stress, public perception, feelings of failure, and uncertainty of recovery13:40: Jason's Veterans Affairs (VA) experience15:40: Veteran's Community Project and other resources for veterans20:00: Therapeutic practices Jason did27:50: Physical sensations associated with PTSD31:40: Imposter syndrome related to being a combat veteran33:05: Working through shame and comparison36:15: How Jason's view of therapy progressed through the process42:30: What Jason would do differently for his mental health if he ran for office again47:05: More on Veterans Community Project and their tiny house program51:50: Recap Support the Podcast: We're now on Patreon! If you'd like to support the podcast, follow this link.Sponsors:Access over 30 at-home lab tests from Everlywell, and head to everlywell.com/beingwell for twenty percent off your next test.Join over a million people using BetterHelp, the world's largest online counseling platform. Visit betterhelp.com/beingwell for 10% off your first month!Want to sleep better? Try the Calm app! Visit calm.com/beingwell for 40% off a premium subscription.MDbio is a plant-based medicine company with natural products that address sleep, anxiety, pain, and immunity. Get your FREE 10-count sample pack by going to mdbiowellness.com and entering the promo code BEINGWELL at checkout!Connect with the show:Subscribe on iTunesFollow Forrest on YouTubeFollow us on InstagramFollow Forrest on InstagramFollow Rick on FacebookFollow Forrest on FacebookVisit Forrest's website